Did you know…

Subclinical riboflavin deficiency is much more widespread than public-health data suggests, especially in high-income countries. The reason is not that the deficiency is well-managed. It is that riboflavin biomarkers are almost never measured in human studies, so the deficit does not appear in the data that guide policy.

The claim, in the words of the Annual Review of Nutrition

The 2023 Annual Review of Nutrition stated the situation with unusual candour for the field:

“Subclinical deficiency may be much more widespread, including in high-income countries, but typically goes undetected because riboflavin biomarkers are rarely measured in human studies. There are adverse health consequences of low and deficient riboflavin status throughout the life cycle, including anemia and hypertension, that could contribute substantially to the global burden of disease.”

— Annual Review of Nutrition, 2023

A Canadian survey has already shown what actual measurement produces: 40% biochemical deficiency in young women with theoretically adequate dietary intake.

The MTHFR interaction that changes the argument

The MTHFR 677C>T polymorphism affects 30 to 60% of the population depending on ethnicity, making it one of the most clinically relevant genetic interactions linked to B2. The reason it matters is simple: MTHFR is a riboflavin-dependent enzyme. In its low-activity variant, the enzyme requires more riboflavin than the average, and it does not function well when riboflavin is depleted:

“MTHFR is therefore a riboflavin-dependent enzyme, and the less riboflavin available, the less functional it becomes. People with the MTHFR 677CT mutation had high homocysteine levels only if they had low riboflavin levels.”

In practice, millions of people carrying the MTHFR polymorphism and taking methylated folate supplements are not getting the expected results, because the underlying B2 deficiency has not been identified and corrected.

The transporter mutation nobody screens for

There is a further level. As the National Organization for Rare Disorders describes:

“When a variant occurs in any of these three [riboflavin transporter] genes, the resulting transporter protein may be abnormal, inefficient or entirely absent. This defect prevents riboflavin from crossing cell membranes, so even if blood levels of vitamin B2 appear normal, cells become starved of this vital nutrient.”

— National Organization for Rare Disorders (NORD)

This entry is a companion to Right to Optimal Riboflavin (B2) Status.